The latter combination therapy resulted in an inflamed tumor microenvironment expressing T cell activating and T cell recruiting chemokines including CXCL9, CXCL10, CXCL11, and Ccl5/RANTES and MIP-1α. The gene discussed is CCL5; the disease is neoplasm.